News & Updates

Use of theophylline as an adjunctive therapy appears to lead to favourable outcomes among patients with bradycardia due to acute spinal cord injury (SCI) with an acceptable response to this agent, suggest the results of a study.

Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).

In the treatment of rheumatoid arthritis (RA), more patients achieve clinical remission with abatacept or certolizumab pegol, but not with tocilizumab, than with active conventional therapy, according to a study.

Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.

Treatment with bezlotoxumab results in a significant decrease in recurrent Clostridioides difficile infection (CDI) in a cohort of immunocompromised patients and transplant recipients, reports a study.

Time to recovery from COVID-19 pneumonia does not appear to differ following treatment with abatacept, cenicriviroc, or infliximab among hospitalized patients, according to a study.